Ensign Peak Advisors, Inc Avidity Biosciences, Inc. Transaction History
Ensign Peak Advisors, Inc
- $55.3 Billion
- Q4 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 27,950 shares of RNA stock, worth $903,064. This represents 0.0% of its overall portfolio holdings.
Number of Shares
27,950
Previous 22,400
24.78%
Holding current value
$903,064
Previous $1.03 Million
21.01%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding RNA
# of Institutions
257Shares Held
110MCall Options Held
341KPut Options Held
366K-
Price T Rowe Associates Inc Baltimore, MD11MShares$357 Million0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.43MShares$305 Million0.0% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$279 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA8.11MShares$262 Million0.04% of portfolio
-
Rtw Investments, LP New York, NY7.93MShares$256 Million3.76% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.68B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...